Mucopolysaccharidoses D009083

Description

Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.   MeSH

Subtype Terms (6)

Mucopolysaccharidosis I
25 drugs (17 approved, 8 experimental)

Mucopolysaccharidosis II
26 drugs (13 approved, 13 experimental)

Mucopolysaccharidosis III
18 drugs (7 approved, 11 experimental)

Mucopolysaccharidosis IV
4 drugs (3 approved, 1 experimental)

Mucopolysaccharidosis VI
18 drugs (12 approved, 6 experimental)

Mucopolysaccharidosis VII
11 drugs (8 approved, 3 experimental)


Phase 3 Indicated Drugs (3)

Phase 1 Indicated Drugs (5)

Other Experimental Indicated Drugs (1)


Organization Involved with Phase 3 Indications (60)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.